Similarly, IL‐15 superagonist co‐delivered with engineered, antigen‐specific DCs showed higher antitumor efficacy (untreated tumors were twice the size of treated tumors) and improved survival in a melanoma mouse model.[97] These investigators also demonstrated the accumulation of CD8+ cytotoxic T cells in the hydrogels.[97] This efficacy, however, was specific against a model antigen (ovalbumin)‐expressing tumor; ovalbumin is a moderately immunogenic protein not expressed naturally in tumors. The gene discussed is CD8A; the disease is neoplasm.